MOS: Educational Resources

Precision Medicine at J&J is working to advance cancer care across multiple diseases with biomarker-informed treatments in oncology.

Posted on 07/01/2025

Scan to visit our website and learn more: Here

Data rates may apply.

New XOFIGO® (radium-223 dichloride) Data in Metastatic Castration-Resistant Prostate Cancer from Phase III PEACE III Trial Published in Annals of Oncology

Posted on 06/09/2025

Annals of Oncology published full results from the pivotal investigational Phase III PEACE III trial, evaluating XOFIGO® (radium-223 dichloride) in combination with enzalutamide, an AR pathway inhibitor (ARPI), versus enzalutamide alone in the first-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases.

View Resource

Cancer of unknown primary (CUP): Implementation of a robust pathway

Posted on 05/27/2025

There is a need to improve upon the diagnostic strategies for cancer of unknown primary (CUP) tumors. And reducing delays in diagnosis and identifying patients at earlier stages may potentially improve patient outcomes. These guides aim to highlight key considerations to take into account when establishing a robust CUP pathway in academic and community centers across the US.

VIew First Resource

View Second Resource

Jazz Pharmaceuticals Study for Adults Suffering from HER2-positive Biliary Tract Cancer

Posted on 05/14/2025

Jazz Pharmaceuticals is sponsoring a clinical study evaluating the safety and efficacy of an investigational medicine called zanidatamab for the treatment of advanced HER2-positive biliary tract cancer. Visit Biliary Tract Cancer Study - Inform Herizon BTC-302 Study - Jazz Pharmaceuticals or click the resource below to learn more.

View Resource

A Phase 3 Study of elacestrant versus standard endocrine therapy in node-positive ER+, HER2- early breast cancer with high risk of recurrence (ELEGANT)

Posted on 05/14/2025

Despite advances in the adjuvant treatment of early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, there continues to be a risk of recurrence. The ELEGANT study is a Global, Multicenter, Randomized, Open-label Phase 3 Study with the primary goal to evaluate the efficacy and safety of elacestrant versus standard endocrine therapy in participants with node-positive ER+/HER2- early breast cancer with high risk of recurrence. The main purpose of this study is to compare the Invasive Breast Cancer-Free Survival (IBCFS) over a period of up to 5 years. 4220 participants will be included in this study around the world. Participants will have equal chance to be assigned to receive either of the treatment combinations.

View Resource